This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Marko Cubrovic: Innovator in Pharmaceutical Chemistry
Introduction
Marko Cubrovic is a notable inventor based in Ridgewood, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target HIV.
Latest Patents
Cubrovic holds a patent for "Crystalline forms of an NRTTI compound." This patent provides novel anhydrate crystalline Forms 1 and 4 of 4'-Ethynyl-2-fluoro-2′-deoxyadenosine. These forms may be useful for inhibiting HIV reverse transcriptase and for the treatment or prophylaxis of HIV infection, as well as for delaying the onset or progression of AIDS or ARC.
Career Highlights
Marko Cubrovic is associated with Merck Sharp & Dohme Corp., a leading global healthcare company. His work focuses on innovative solutions to combat viral infections, showcasing his commitment to improving public health.
Collaborations
Cubrovic has collaborated with esteemed colleagues such as Daniel Skomski and Wei Xu. Their combined expertise contributes to the advancement of research in pharmaceutical sciences.
Conclusion
Marko Cubrovic's contributions to pharmaceutical chemistry, particularly in the fight against HIV, highlight his role as an influential inventor. His work continues to pave the way for innovative treatments that can significantly impact global health.